| Autor: |
Frustaci, A. M., Montillo, M., Rossi, D., Zinzani, P. L., Motta, M., Gaidano, G., Quaresmini, G., Scarfò, L., Pietrasanta, D., Coscia, M., Deodato, M., Zamprogna, G., Cairoli, R., Stüssi, G., Zucca, E., Pileri, S., Zenz, T., Tedeschi, A. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p62-63, 2p |
| Abstrakt: |
RS mutation profile was tested on pre-treatment cell free DNA. Rate of unmeasurable MRD and impact of mutations and chronic lymphocytic leukemia-RS clonal relation on outcomes will be presented at the meeting. B Introduction: b Chemoimmunotherapy is the standard first line treatment of diffuse large B-cell lymphoma (DLBCL) variant of Richter syndrome (RS). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text